目次

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Nephrotic Syndrome - Overview
Nephrotic Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Nephrotic Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nephrotic Syndrome - Companies Involved in Therapeutics Development
Adare Pharma Solutions
APIE Therapeutics Inc
Asahi Kasei Pharma Corp
ChemoCentryx Inc
NephKey Therapeutics Inc
Ninevah Therapeutics SL
Pharmapraxis
SynAct Pharma AB
Nephrotic Syndrome - Drug Profiles
AP-1189 - Drug Profile
Product Description
Mechanism Of Action
History of Events
APT-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
APT-102 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ilacirnon sodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
mizoribine - Drug Profile
Product Description
Mechanism Of Action
History of Events
NTX-014 - Drug Profile
Product Description
Mechanism Of Action
pioglitazone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
prednisone - Drug Profile
Product Description
Mechanism Of Action
History of Events
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
Nephrotic Syndrome - Dormant Projects
Nephrotic Syndrome - Product Development Milestones
Featured News & Press Releases
Nov 23, 2021: SynAct Pharma reports positive PK data on AP1189 tablets
Nov 11, 2021: SynAct Pharma takes advantage of new toxicology results and new tablet formulation to re-design and optimize the study programme with AP1189 in Nephrotic Syndrome
Aug 25, 2021: SynAct strengthens IP portfolio - Grant of key European patent covering AP1189
Jun 29, 2020: SynAct Pharma has initiated the Phase II clinical study with AP1189 in Nephrotic Syndrome
Jun 02, 2020: SynAct Pharma´s clinical trial application for AP1189 in Nephrotic Syndrome approved by the Danish Medical Agency
Mar 31, 2020: SynAct Pharma submits clinical trial application for AP1189 in Nephrotic Syndrome
Mar 31, 2020: SynAct Pharma investigates the possibility of AP1189 as additional therapy in hospitalized patients with COVID-19
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Nephrotic Syndrome, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Nephrotic Syndrome - Pipeline by Adare Pharma Solutions, 2022
Nephrotic Syndrome - Pipeline by APIE Therapeutics Inc, 2022
Nephrotic Syndrome - Pipeline by Asahi Kasei Pharma Corp, 2022
Nephrotic Syndrome - Pipeline by ChemoCentryx Inc, 2022
Nephrotic Syndrome - Pipeline by NephKey Therapeutics Inc, 2022
Nephrotic Syndrome - Pipeline by Ninevah Therapeutics SL, 2022
Nephrotic Syndrome - Pipeline by Pharmapraxis, 2022
Nephrotic Syndrome - Pipeline by SynAct Pharma AB, 2022
Nephrotic Syndrome - Dormant Projects, 2022

List of Figures
Number of Products under Development for Nephrotic Syndrome, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022